Cargando…
Cardiovascular disease incidence rates: a study using routinely collected health data
BACKGROUND: There is substantial evidence that systemic anticancer therapies and radiotherapy can increase the long-term risk of cardiovascular disease (CVD). Optimal management decisions for cancer patients therefore need to take into account the likely risks from a proposed treatment option, as we...
Autores principales: | Ramroth, Johanna, Shakir, Rebecca, Darby, Sarah C., Cutter, David J., Kuan, Valerie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10647140/ https://www.ncbi.nlm.nih.gov/pubmed/37968715 http://dx.doi.org/10.1186/s40959-023-00189-8 |
Ejemplares similares
-
P077: Predicting radiotherapy dose to the heart and the risk of radiation-related cardiac toxicity for Hodgkin lymphoma patients, using pre-chemotherapy PET-CT scans
por: Shakir, Rebecca, et al.
Publicado: (2022) -
P095: Personalised Modelling of Quality-Adjusted Survival Benefit and Cost-Effectiveness of using Proton Beam Therapy inthe Treatment of Intermediate-Stage Hodgkin Lymphoma in England
por: Jones, David, et al.
Publicado: (2022) -
Proton Therapy in Supradiaphragmatic Lymphoma: Predicting Treatment-Related Mortality to Help Optimize Patient Selection
por: Ntentas, Georgios, et al.
Publicado: (2022) -
Informing radiotherapy decisions in stage I/IIa Hodgkin lymphoma: modeling life expectancy using radiation dosimetry
por: Jones, David A., et al.
Publicado: (2022) -
Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography–Directed Therapy for Early-Stage Hodgkin Lymphoma
por: Cutter, David J., et al.
Publicado: (2021)